TrialBlood2025

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.

Peng-Peng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.